NCT06424301

Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

RecruitingEARLY_PHASE1INTERVENTIONAL

Trial Details

Start: 2024-12-20Est. Completion: 2025-09-30

Enrollment target: 2 participants

Locations

Contact

Neurofibromatosis 1

Background: NF1 is a genetic disease that causes tumors called atypical neurofibromas. These tumors, which arise from n…

Bethesda, United StatesEst. completion Dec 31, 2028

NSCLCMetastatic Colorectal CarcinomaRefractory Melanoma

The primary goal of this trial is to assess clinical response to nivolumab and pixatimod, and, nivolumab, pixatimod and …

Pittsburgh, United StatesCompleted Feb 5, 2024

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.